MYC and neoplasm: Cytotoxicity assays revealed comparable tumor cell killing between TriBAFF/CD3/ABDCon and Myc-BAFF-based sCAR-T cells; however, TriBAFF/CD3/ABDCon showed slightly reduced activity at low concentrations (Fig. S9A).